The effect of ezetimibe on androgen production in hypercholesterolemic women with polycystic ovary syndrome

Cardiovascular Therapeutics

Volumn 32, Issue 5, 2014, Pages 219-223

  Krysiak, Robert ^a   Zmuda, Witold ^b   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Invasive Cardiology   (Poland)

Author keywords

Androgens; Ezetimibe; Hypercholesterolemia; Insulin resistance; Polycystic ovary syndrome; Simvastatin

Indexed keywords

AZETIDINE DERIVATIVE; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TESTOSTERONE;

ADULT; BIOSYNTHESIS; BLOOD; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; OVARY POLYCYSTIC DISEASE;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; SIMVASTATIN; TESTOSTERONE;

EID: 84908453511     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12088     Document Type: Article

References (28)

1. Krysiak R, Okopien B, Gdula-Dymek A, Herman ZS. Update on the management of polycystic ovary syndrome. Pharmacol Rep 2006;58:614-625.
2. Scicchitano P, Dentamaro I, Carbonara R, et al. Cardiovascular risk in women with PCOS. Intern J Endocrinol Metab 2012;10:611-618.
3. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007;92:456-461.
4. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009;94:4938-4945.
5. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dulabe AJ. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab 2011;96:3493-3501.
6. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009;94:103-108.
7. Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril 2010;94:2208-2213.
8. Celik O, Acbay O. Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. J Endocrinol Invest 2012;35:905-910.
9. Raja-Khan N, Kunselman AR, Hogeman CS, Stetter CM, Demers LM, Legro RS. Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertil Steril 2011;95:1849-1852.
10. Gao L, Zhao FL, Li SC. Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Exp Clin Endocrinol Diabetes 2012;120:367-375.
11. Schaefer JR. Lipid management for the prevention of cardiovascular disease. Curr Pharm Design 2011;17:852-860.
12. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins - clinical evidence. Curr Pharm Design 2009;15:479-489.
13. Palaniswamy C, Selvaraj DR, Selvaraj T, Sukhija R. Mechanisms underlying pleiotropic effects of statins. Am J Ther 2010;17:75-78.
14. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Design 2009;15:490-516.
15. Miura S, Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med 2008;47:1165-1170.
16. Krysiak R, Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol 2011;57:505-512.
17. Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 2012;271:32-42.
18. Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. Fundam Clin Pharmacol 2012;26:424-431.
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
20. de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 2011;17:495-500.
21. Ciccone MM, Favale S, Bhuva A, et al. Anteroposterior diameter of the infrarenal abdominal aorta is higher in women with polycystic ovary syndrome. Vasc Health Risk Manag 2009;5:561-566.
22. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276-1284.
23. Bajuk Studen K, Jensterle Sever M, Pfeifer M. Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome. Front Horm Res 2013;40:64-82.
24. Miller WL. Steroidogenic enzymes. Endocr Dev 2008;13:1-18.
25. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007;59:483-499.
26. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 2004;82(Suppl 3):1193-1197.
27. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 2008;359:2195-2207.
28. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.